-transparent.png){kind=logo}
As a primary care physician for women, the gynecologist frequently is faced with management of patients who have benign breast disease. Mammary dysplasia, or fibrocystic disease, clinically presents a difficult management problem, both in terms of relieving the patients' symptomatology and of detecting occult malignancy. Traditionally, diuretics, salt restriction, and hormone therapies have been recommended. Recently, data concerning nutritional impact on this disease process, including methylxanthine restriction and tocopherol therapy, have been reported. New, effective pharmacologic agents also are now available. This article reviews the efficacy of these therapeutic regimens and recommends a rational approach for the management of patients with mammary dysplasia.
R S London, and
G S Sundaram, and
P J Goldstein
June 1979,
The Medical journal of Australia,
R S London, and
G S Sundaram, and
P J Goldstein
June 1960,
Archivio "de Vecchi" per l'anatomia patologica e la medicina clinica,
R S London, and
G S Sundaram, and
P J Goldstein
May 1992,
The Veterinary clinics of North America. Small animal practice,
R S London, and
G S Sundaram, and
P J Goldstein
July 1972,
The Medical journal of Australia,
R S London, and
G S Sundaram, and
P J Goldstein
September 1979,
The Medical journal of Australia,
R S London, and
G S Sundaram, and
P J Goldstein
September 1979,
The Medical journal of Australia,
R S London, and
G S Sundaram, and
P J Goldstein
January 1964,
Annali italiani di chirurgia,
R S London, and
G S Sundaram, and
P J Goldstein
October 1959,
Texas state journal of medicine,
R S London, and
G S Sundaram, and
P J Goldstein
November 1953,
Giornale di scienze mediche,
R S London, and
G S Sundaram, and
P J Goldstein
July 1953,
Das Deutsche Gesundheitswesen,
